Pharmacopeia gets Bristol exec
Executive Summary
Rene Belder, who led Bristol-Myers Squibb's regulatory team for the PPAR agonist Pargluva (muraglitazar), joins Pharmacopeia as VP-clinical and regulatory affairs, the Princeton, N.J. biotech announces Nov. 6. Bristol halted development of Pargluva in May, seven months after an FDA "approvable" letter for the diabetes agent suggested additional clinical trials would be necessary (1"The Pink Sheet" Dec. 19, 2005, p. 11). At Pharmacopeia, Belder will be responsible for overseeing the firm's current and future clinical development product portfolio...
You may also be interested in...
Bristol Swallows Cost-Cutting Pill To Dull Pargluva Pain; Sales Force May Shrink
Bristol-Myers Squibb will undertake a cost-cutting program to offset the impact of the development delay of the investigational type 2 diabetes drug Pargluva.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.